Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease
Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial
Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…Treatment of secondary movement disorders related to midbrain cavernomas
Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…Essential Tremor and Depression
Objective: To determine if depression and neuropsychiatric symptoms are more prevalent in patients with essential tremor (ET) compared with non-ET controls and if so, to establish…Forehead Tremor: a clinical presentation of ocular Myasthenia Gravis?
Objective: The case of a patient with seropositive Myasthenia gravis (MG), presenting with forehead tremor, is reported. Background: The clinical presentation of MG with involuntary movements…Targeting the intracellular localization of Ataxin-3 as novel treatment strategy for Spinocerebellar Ataxia Type 3
Objective: Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is an autosomal-dominantly inherited neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene…TANDEM REPEATS BEYOND THE CLINICAL DIAGNOSIS IN ADCAs
Objective: To present observations on abnormal expansion in both allele in ADCAs. Background: Use of expansion in tandem repeats is restricted to only disease diagnosis…Eye Movements in Huntington Disease Like 2
Objective: ObjectiveTo determine if eye movements are preserved in Huntington Disease-Like 2 (HDL2) and if this can be used to differentiate HDL2 from Huntington Disease…Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Objective: To assess the neurobiological substrate of initial cognitive decline in Parkinson’s disease (PD) to inform patient management, clinical trial design, and development of treatments.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 155
- Next Page »